Ionis and Akcea launch Phase III trial to treat polyneuropathy
Ionis and Akcea have launched a Phase III clinical trial of AKCEA-TTR-L to treat polyneuropathy in patients with hereditary TTR (hATTR) amyloidosis. Credit: Ed Uthman via Flickr.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.ContinueLearn more